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Natural killer (NK) cells constitute a distinct lineage of lym- 
phocytes that kill a variety of target cells, including tumor 
cells, cells infected with some viruses or bacteria, and 
some normal cell types. NK cells resemble cytotoxic T 
lymphocytes (CTLs) in some respects, including cytokine 
production and the use of the perforin-dependent cytolytic 
machinery. Significantly, however, NK cells do not ex- 
press T cell receptors or immunoglobulins, and they are 
apparently unaffected by defects in the V-D- J  recombina- 
tion machinery. Furthermore, early efforts to define dis- 
crete patterns of recognition by NK cells met with failure, 
leading to the notion that NK recognition is "primitive." 
However, recent results suggest that target cell lysis by NK 
cells is regulated by a balance between specific activating 
and inhibitory receptors. A major component of recogni- 
tion involves receptors specific for class I major histocom- 
patibility complex (MHC) molecules on target cells, en- 
gagement of which inhibits N K lysis. Thus, cells exhibiting 
abnormal or reduced amounts of class I molecules, which 
are therefore invisible to CTLs, are killed by NK cells. The 
recent characterization of several novel recognition struc- 
tures on NK cells has added a wealth of new information, 
but at the same time has generated a number of fascinat- 
ing puzzles. 
Recognition of Class I MHC Molecules by NK Cells 
The role of NK ceils in bone marrow allograft rejection 
was the initial hint that they recognize MHC molecules 
(for review see Yu et al., 1992). Then it was discovered 
that the sensitivity of many tumor cells to lysis by NK cells 
in vitro is inversely related to the levels of MHC class I 
molecules on the tumor cells (for review see Ljunggren and 
Karre, 1990), a finding later extended to nontransformed 
lymphoblasts from class I-deficient mice (Liao et al., 1991). 
Class I molecules on target cells somehow prevent NK 
cell-mediated lysis. 
The situation proved more complex when it was appreci- 
ated that NK cells can discriminate class I alleles. Human 
NK clones were shown to lyse allogeneic T cell blasts, and 
the target cell genes controlling susceptibility to lysis were 
mapped to the MHC (Ciccone et al., 1992). In the murine 
system, an NK cell subset defined by expression of the 
Ly49A moleculewas hown to discriminate between tumor 
target cells expressing different MHC haplotypes (Karl- 
hofer et al., 1992). 
Class I Expression by Target Cells Inhibits NK Cells 
and Activates T Cells 
Fragments of intracellular protein antigens are presented 
by MHC class I molecules on the cell surface. Hence, class 
I molecules allow specific recognition and lysis of infected 
Minireview 
cells by CTLs. NK cells behave in exactly the opposite 
fashion, in that expression of class I genes generally ren- 
ders target cells resistant to lysis (Storkus et al., 1989; 
Ljunggren and Karre, 1990; Karlhofer et al., 1992). Why 
should NK cell lysis be inhibited by class I molecules ex- 
pressed on target cells? The obvious possibility is that a 
key function of NK cells is to monitor the integrity of class 
I expression. Repression of class I expression either di- 
rectly or via the class I antigen processing pathway is a 
strategy employed by many viruses to hide from CTLs 
within infected cells. Similarly, metastatic tumor cells often 
exhibit repressed class I expression, perhaps owing to 
selection by CTLs. Repression of class I expression by 
any mechanism would in most cases render cells sensitive 
to lysis by NK cells. Thus, the development of a monitoring 
system for class I expression makes sense evotutionarily. 
Identification of Class I-Specific Inhibitory 
Receptors on NK Cells 
The general consensus is that class I inhibition of NK cells 
is accomplished by class I-specific NK cell receptors, 
which transduce signals that inhibit the lytic machinery 
(Figure 1). The recent identification of putative MHC class 
I-specific receptors on NK cells in both the murine and 
human systems supports this view. In the murine system, 
the Ly49A molecule defines a subset of 10%-20% of NK 
cells that lyses cells of the H-2 ~ MHC haplotype, but not 
cells expressing the D d MHC class I gene (Karlhofer et 
al., 1992). Furthermore, Ly49A binds to the D a molecule 
(Kane, 1994; Daniels et al., 1994a). Blocking either Ly49A 
or D d with antibodies prevents inhibition of NK cell lysis, 
suggesting that Ly49A represents a Da-specific inhibitory 
NK receptor. 
In the human system, several monoclonal antibodies 
reactive to the p58 family of cell surface receptors define 
NK cell subsets that exhibit distinct human lymphocyte 
antigen (HLA) (human MHC) specificities. For example, 
NK clones that stain with the GL183 anti-p58 antibody are 
specifically inhibited by target cells expressing HLA-Cw3 
and related alleles (Moretta et al., 1993), and those that 
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bind the anti-NKB1 antibody are inhibited by HLA-Bw4 
expression in target cells (Litwin et al., 1994; D'Andrea et 
al., 1995). Antibodies against either the p58 receptor or 
the corresponding HLA molecule restore lysis of cells ex- 
pressing the inhibitory HLA allele. While binding of p58 
molecules to class I molecules has not been reported, the 
results seem to parallel the mouse data in other respects. 
Surprisingly, however, the p58 receptors and the Ly49 
receptors are about as dissimilar in structure as cell sur- 
face receptors can be. 
Structure and Expression of Ly49 and p58 
NK Cell Receptors 
Ly49A is a disulfide-linked imeric glycoprotein of 44 kDa 
subunits (Figure 2). The cDNA sequence indicated that 
Ly49A is a type II membrane glycoprotein and that a major 
segment of the extracellular domain exhibits homology to 
the C-type lectin super family (Yokoyama and Seaman, 
1993). Indeed, recent evidence suggests that glycans on 
D d class I molecules contribute to the interaction with 
Ly49A (Daniels et al., 1994b), though the discrimination 
of class I alleles by Ly49A suggests interactions with the 
class I polypeptide chain as well. At least seven additional 
related cDNAs were isolated by hybridization with Ly49A 
cDNA, defining a small family of NK cell receptor genes 
closely linked on mouse chromosome 6. Interestingly, 
Ly49 genes undergo allelic exclusion in NK cells, consis- 
tent with an important role of these receptors in mediating 
specific NK cell recognition (Held et al., 1995). Three Ly49 
family members with distinct specificities were defined 
with monoclonal antibodies (Karlhofer et al., 1992; Stone- 
man et al., 1995; Mason et al., 1995). These receptors are 
expressed on distinct but overlapping NK cell subsets, 
together accounting for more than 75% of NK cells. These 
findings suggest that Ly49 receptors are expressed by 
most, if not all, NK cells. 
In contrast, the sequences of the newly cloned human 
p58 receptors uggest they are type I membrane glycopro- 
teins and members of the immunoglobulin superfamily 
(Wagtmann et al., 1995; Colonna and Samaridis, 1995) 
(Figure 2). The distinct structures of p58 and Ly49 recep- 
tors account for earlier findings that p58 receptors are 
larger (58 kDa) th an Ly49 molecules and are not covalently 
dimerized. Furthermore, p58 genes map to chromosome 
19, nonsyntenic to Ly49 genes. 
Like the Ly49 family, the p58 receptors represent a fam- 
ily of proteins. At least nine distinct but related sequences 
have been deduced from cDNA sequencing, though some 
of these may represent alleles. Gene expression studies 
indicated that every NK cell clone examined expressed 
one or more p58 receptor. 
Too Many Receptors? 
If until recently NK cell receptors were too few, now there 
seems to be too many. Currently, p58 receptors have not 
been identified in the mouse. While NK-specific type II 
lectin-like membrane proteins have been identified on hu- 
man NK cells, there is presently no agreement hat these 
receptors represent human Ly49 homologs (Chang et al., 
1995; Yabe et al., 1993). It seems unlikely, however, that 
the p58 and Ly49 receptor families arose so late in evolu- 
Extracellular TM Cytop lasmic  
NH2~ 319 ~ 84 ICOOH p70 
, , ~ ~ , , 
S- -$  S - -S  
m 224 m 76/84  I p58  
pS8-RELATED I I I I 
RECEPTOR S S S- -S  
ISOFORMS pSO 
I I  224 ~ 39 I (putative 
I I [ I 
S S S - -S  s t ructure)  
LY49 COOHI 196 ~44 ]NH 2 
RECEPTORS I 
P 
C00H I 196 ~ 44 INH 2 
Figure 2. Structures of p58-Related and Ly49 Receptors 
p70, p58, and the putative p50 receptors represent isoforrns of the 
immunoglobulin-related family of class I-specific NK cell receptors. 
Each disulfide bridge corresponds to an imrnunogtobulin domain. The 
class I-specific Ly49 receptors are type II lectin-like (and probably 
hornodirneric) proteins. The site of the disulfide bridge is not known. 
The number of amino acids in the intracellular nd extracellular do- 
mains are indicated. 
tion as to be distinct in mouse and human. Barring that 
possibility, the ubiquitous expression of Ly49 and p58 re- 
ceptors in most NK cells of mice and humans, respectively, 
would suggest that both receptor families may be coex- 
pressed by most, if not all, individual NK cells. 
Why should there be two unrelated receptor families to 
accomplish what is ostensibly the same task? One possi- 
bility is that human Ly49 homologs are devoted to recogni- 
tion of HLA-A molecules, which are known to inhibit NK 
cells but have not yet been paired with any p58 receptors. 
However, different murine Ly49 receptors interact with D, 
L, and possibly K molecules (Yokoyama and Seaman, 
1993; Bennett et al., 1995; Mason et al., 1995), suggesting 
that this class of molecules does not discriminate between 
different class I loci. 
Another possibility is that the two receptor families are 
functionally redundant. However, while examples have 
been reported of clones expressing two functional p58 
receptors with different HLA specificities, it would seem 
counterproductive for NK cells generally to express recep- 
tors for more than one self class I molecule: these cells 
would be unable to lyse target cells that had extinguished 
expression of only one of the class I molecules. Further- 
more, the inhibition of lysis caused by transfected class 
I genes in target cells can often be reversed by antibodies 
against a single p58 or Ly49 receptor, suggesting that 
these NK cells may not express other receptors with the 
same class I specificity. The present data are not incom- 
patible with the existence of NK clones in which members 
of both receptor families are functionally active, but it re- 
mains unclear how the activities of the two receptor fami- 
lies would be coordinated. 
Discrimination of Class I-Bound Peptides by 
NK Cells? 
Class I molecules on cells are complexed with many differ- 
ent cellular peptides. If class I-specific NK cell receptors 
recognize only specific peptide-class I complexes, target 
cells could be rendered NK sensitive by displacement of 
the relevant peptides by viral antigens as well as by class 
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I repression. Peptide-transporter-deficient cell lines were 
used to assess the peptide specificity of class I recognition 
by NK cells. Whereas the murine Ly49A ÷ NK subset failed 
to discriminate different peptides bound to D d (Correa and 
Raulet, 1995), two examples of human NK clones were 
described that appear to discriminate B27-bound peptides 
(Malnati et al., 1995). Further studies will be necessary to 
resolve whether this reflects the use of the different recep- 
tor families or some other experimental differences. 
Isoforms of p58.Related Receptors Suggest 
Functional Heterogeneity 
The cDNA sequences of p58-related receptors reveal two 
forms of length heterogeneity (Wagtmann et al., 1995; Co- 
Ionna and Samaridis, 1995) (Figure 2). In the extracellular 
domain, some of the sequences contain two immunoglob- 
ulin loops, whereas others contain three immunoglobulin 
loops. The sequences containing two immunoglobulin loops 
presumably encode the 58 kDa receptors, whereas a se- 
quence containing three immunoglobulin loops encodes 
the previously described 70 kDa inhibitory receptor de- 
fined by the anti-NKB1 monoclonal antibody (D'Andrea et 
al., 1995). At present, the significance of this heterogeneity 
is unclear. 
On the other hand, heterogeneity observed in the trans- 
membrane regions and cytoplasmic tails may account for 
putative signaling differences by p58-related isoforms. 
Seven of the published sequences have cytoplasmic tails 
of 76 or 84 amino acids, containing two YxxL sequences 
characteristic of antigen receptor activation motifs (ARAMs) 
found in antigen receptor-associated molecules such as 
the CD3 chains. However, the p58 YxxL sequences are 
separated by 26 amino acids rather than the 6-8 amino 
acids found in CD3 chains. The difference in spacing may 
contribute to the different signaling properties of CD3 
chains (activation) versus p58 receptors (inhibition). Inter- 
estingly, two of the p58-1ike sequences contain a shorter 
(39 amino acid) cytoplasmic tail, lacking the ARAM-like 
sequences, raising the possibility that these receptors may 
signal differently. 
In fact, evidence from the mouse, rat, and human sys- 
tems suggests that MHC molecules on target cells may 
sometimes activate rather than inhibit lysis. Recently, a 
shorter (50 kDa) version of the p58 receptor was identified 
that apparently mediates class I-specific NK cell activa- 
tion (Moretta et al., 1995). It is thus tempting to speculate 
that activating receptors belong to the p58-related recep- 
tor family but contain the shorter cytoplasmic tails de- 
scribed above. Interestingly, the sequences with the shorter 
cytoplasmic tails contain charged (lysine) residues in their 
transmembrane region. By analogy with T cell receptors, 
the lysine residues may pair with other activating mole- 
cules such as CD3 chains. While the structural heteroge- 
neity of p58-related receptors may account for their distinc- 
tive functional heterogeneity, at present it is entirely 
unclear why NK cells should have evolved the capacity 
to destroy cells expressing specific class I molecules. 
Other Activating Receptors for NK Cells? 
The role of class I-specific activating receptors on NK 
cells is obscure, but the existence of activating receptors 
specific for tumor cells has long been predicted. The NKR- 
P1 proteins (Chambers et al., 1989) are encoded by a 
small family of related genes that are closely linked to Ly49 
and also encode type II membrane proteins with lectin 
domains (Yokoyama and Seaman, 1993). Recently, evi- 
dence has accumulated that NKR-P1 proteins participate 
in activating the lysis of some (but probably not all) tumor 
cells (Bezouska et al., 1994; Ryan et al., 1995), possibly 
by interacting with oligosaccharide ligands (Figure 2). Ad- 
ditionally, Fc receptors on NK cells mediate cytotoxicity 
of antibody-coated target cells. Importantly, engagement 
of inhibitory receptors can often overrule the activating 
signals, suggesting that the outcome of an NK cell-target 
cell interaction may be determined by the balance of the 
two types of signals. 
Outstanding Questions 
While great progress has been made in the field of NK 
cell specificity, many new questions are prompted by the 
recent results. Are both the Ly49 and p58 inhibitory recep- 
tor families present in the same species? If so, are their 
specificities distinct, and how are their activities coordi- 
nated in individual NK cells? What are the mechanisms 
that distribute expression of different class I receptors to 
distinct (though overlapping) subsets, resulting in the for- 
mation of the NK repertoire? How are potentially autoag- 
gressive NK clones silenced? What is the funclion of puta- 
tive activating class I-specific NK receptors? What signal 
transduction pathways are employed by the inhibitory re- 
ceptors? Finally, are NK cells really so primitive? If the 
chief function of the class I inhibitory system is to monitor 
the integrity of class I expression and if class I molecules 
function primarily to present antigens to T cells, the class 
I inhibitory receptors may have evolved after the T cell 
system and not before. Are NK cells modern, or do the 
class I inhibitory receptors represent recently added equip- 
ment to an ancient cell type? 
References 
Bennett, M., Yu, Y. Y. L., Stoneman, E., Ftembecki, FI. M., Mathew, 
P. A., Fischer lindahl, K., and Kumar, V. (1995). Semin. Immunol. 7, 
121-127. 
Bezouska, K., Yuen, C. T., Obrien, J., Childs, R. A., Chai, W. G., 
Lawson, A. M., Drbal, K., Fiserova, A., Pospisil, M., and Feizi, T. (1994). 
Nature 372, 150-157. 
Chambers, W. H., Vujanovic, N. L., DeLeo, A. B., Olszowy, M. W., 
Herberrnan, R. B., and Hiserodt, J. C. (1989). J Exp. Med. 169, 1373- 
1389. 
Chang, C., Rodriguez, A., Carretere, M., Lopez-Botet, M., Phillips, J., 
and Lanier, L. (1995). Eur. J. Immunol., in press. 
Ciccone, E., Pende, D., Viale, O., Than, A., Di Donate, C., Orengo, 
A. M., Biassoni, Ft., Verdiani, S., Amoroso, A., Moretta, A., and Moretta, 
L. (1992). J. Exp. Med. 178, 963-971. 
Colonna, M., and Samaridis, J. (1995). Science 268, 405-408. 
Correa, I., and Raulet, D. H. (1995). Immunity 2, 61-71. 
D'Andrea, A., Chang, C., Bacon, K., McClanahan, T., Phillips, J., and 
Lanier, L. L. (1995). J. Immunol., in press. 
Daniels, B. F., Karlhofer, F. M., Seaman, W. E., and Yokoyama, W. M. 
(1994a). J. Exp. Med. 180, 687-892. 
Daniels, B. F., Nakamura, M. C., Rosen, S. D., Yokoyarna, W. M., 
and Seaman, W. E. (1994b). Immunity 1, 785-792. 
Cell 
700 
Held, W., Roland, J., and Raulet, D. H. (1995). Nature 376, 355-358. 
Kane, K. (1994). J. Exp. Med. 179, 1011-1015. 
Karlhofer, F. M., Ribaudo, R. K., and Yokoyama, W. M. (1992). Nature 
358, 66-70. 
Liao, N., Bix, M., Zijlstra, M., Jaenisch, R., and Raulet, D. (1991). 
Science 253, 199-202. 
Litwin, V., Gumperz, J., Parham, P., Phillips, J., and Lanier, L. L. 
(1994). J. Exp. Med. 180, 537-543. 
Ljunggren, H. G., and Karre, K. (1990). Immunol. Today 11,237-244. 
Malnati, M. S., Peruzzi, M., Parker, K. C., Biddison, W. E., Ciccone, 
E., Moretta, A., and Long, E. O. (1995). Science 267, 1016-1018. 
Mason, L. H., Ortaldo, J. R., Young, H. A., Kumar, K., Bennett, M., 
and Anderson, S. K. (1995). J. Exp. Med. 182, 293-303. 
Moretta, A., Vitale, M., Borrino, C., Orengo, A., Morelli, L., Augugliaro, 
R., Barbaresi, M., Ciccone, E., and Moretta, L. (1993). J. Exp. Med. 
178, 597-604. 
Moretta, A., Sivori, S., Vitale, M, Pende, D., Morelli, L., Augugliaro, 
R., Bottino, C., and Moretta, L. (1995). J. Exp. Med., in press. 
Ryan, J., Niemi, E., Nakamura, M., and Seaman, W. (1995). J. Exp. 
Med. 181, 1911-1915. 
Stoneman, E., Bennett, M., An, J., Chesnut, K., Wakeland, E., 
Scheerer, J., Siciliano, M., Kumar, V., and Mathew, P. (1995). J Exp. 
Med. 182, 305-313. 
Storkus, W. J., Alexander, J., Payne, J. A., Dawson, J. R., and Cress- 
well, P. (1989). Proc. Natl. Acad. Sci. USA 86, 2361-2364. 
Wagtmann, N., Biassoni, R., Cantoni, C., Verdiani, S., Malnati, M., 
Vitale, M., Bottino, C., Moretta, L., Moretta, A., and Long, E. (1995). 
Immunity 2, 439-449. 
Yabe, T., McSherry, C., Bach, F. H., Fisch, P., Schall, R., Sondel, 
P. M., and Houchines, J. P. (1993). Immunogenetics 37, 455-460. 
Yokoyama, W. M., and Seaman, W. E. (:1993). Annu. Rev. Immunol. 
11,613-635. 
Yu, Y. Y. L., Kumar, V., and Bennett, M. (1992). Annu. Rev. Immunol. 
10, 189-213. 
